IL17A and pyoderma gangrenosum: Here, we present the challenging clinical course of a patient who developed pyoderma gangrenosum during anti-IL-17 therapy for undifferentiated oligoarthritis, culminating in complete resolution following targeted IL-36 pathway inhibition with spesolimab.